Applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into
more effective and safer medicines.
Learn more about our leading ProTide candidates and our clinical studies
NUC-3373 is being investigated in two clinical studies including a Phase 1b/2 study in patients with advanced colorectal cancer.
NUC-7738 is being investigated in a Phase 1/2 study for patients with advanced solid tumors.
Acelarin (NUC-1031) Studies
Acelarin has been evaluated in several clinical studies